Literature DB >> 29785260

COMBATING NRAS MUTANT MELANOMA: FROM BENCH TO BEDSIDE.

Ileabett M Echevarría-Vargas1, Jessie Villanueva1,2.   

Abstract

Entities:  

Keywords:  NRAS; clinical trials; drug combinations; immunotherapy; melanoma

Year:  2017        PMID： 29785260      PMCID： PMC5959291          DOI： 10.2217/mmt-2017-0023

Source DB:  PubMed          Journal:  Melanoma Manag        ISSN： 2045-0885


× No keyword cloud information.
  18 in total

1.  NRAS mutation status is an independent prognostic factor in metastatic melanoma.

Authors:  John A Jakob; Roland L Bassett; Chaan S Ng; Jonathan L Curry; Richard W Joseph; Gladys C Alvarado; Michelle L Rohlfs; Jessie Richard; Jeffrey E Gershenwald; Kevin B Kim; Alexander J Lazar; Patrick Hwu; Michael A Davies
Journal:  Cancer       Date:  2011-12-16       Impact factor: 6.860

2.  BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy.

Authors:  Miguel F Segura; Bárbara Fontanals-Cirera; Avital Gaziel-Sovran; María V Guijarro; Doug Hanniford; Guangtao Zhang; Pilar González-Gomez; Marta Morante; Luz Jubierre; Weijia Zhang; Farbod Darvishian; Michael Ohlmeyer; Iman Osman; Ming-Ming Zhou; Eva Hernando
Journal:  Cancer Res       Date:  2013-08-15       Impact factor: 12.701

Review 3.  Targeting bromodomains: epigenetic readers of lysine acetylation.

Authors:  Panagis Filippakopoulos; Stefan Knapp
Journal:  Nat Rev Drug Discov       Date:  2014-04-22       Impact factor: 84.694

Review 4.  RAS Proteins and Their Regulators in Human Disease.

Authors:  Dhirendra K Simanshu; Dwight V Nissley; Frank McCormick
Journal:  Cell       Date:  2017-06-29       Impact factor: 41.582

5.  In Vivo Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype.

Authors:  Daniela Bossi; Angelo Cicalese; Gaetano I Dellino; Lucilla Luzi; Laura Riva; Carolina D'Alesio; Giuseppe R Diaferia; Alessandro Carugo; Elena Cavallaro; Rossana Piccioni; Massimo Barberis; Giovanni Mazzarol; Alessandro Testori; Simona Punzi; Isabella Pallavicini; Giulio Tosti; Luciano Giacó; Giorgio Melloni; Timothy P Heffernan; Gioacchino Natoli; Giulio F Draetta; Saverio Minucci; PierGiuseppe Pelicci; Luisa Lanfrancone
Journal:  Cancer Discov       Date:  2016-05-13       Impact factor: 39.397

6.  Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.

Authors:  Reinhard Dummer; Dirk Schadendorf; Paolo A Ascierto; Ana Arance; Caroline Dutriaux; Anna Maria Di Giacomo; Piotr Rutkowski; Michele Del Vecchio; Ralf Gutzmer; Mario Mandala; Luc Thomas; Lev Demidov; Claus Garbe; David Hogg; Gabriella Liszkay; Paola Queirolo; Ernesto Wasserman; James Ford; Marine Weill; L Andres Sirulnik; Valentine Jehl; Viviana Bozón; Georgina V Long; Keith Flaherty
Journal:  Lancet Oncol       Date:  2017-03-09       Impact factor: 41.316

7.  Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.

Authors:  Weiyi Peng; Jie Qing Chen; Chengwen Liu; Shruti Malu; Caitlin Creasy; Michael T Tetzlaff; Chunyu Xu; Jodi A McKenzie; Chunlei Zhang; Xiaoxuan Liang; Leila J Williams; Wanleng Deng; Guo Chen; Rina Mbofung; Alexander J Lazar; Carlos A Torres-Cabala; Zachary A Cooper; Pei-Ling Chen; Trang N Tieu; Stefani Spranger; Xiaoxing Yu; Chantale Bernatchez; Marie-Andree Forget; Cara Haymaker; Rodabe Amaria; Jennifer L McQuade; Isabella C Glitza; Tina Cascone; Haiyan S Li; Lawrence N Kwong; Timothy P Heffernan; Jianhua Hu; Roland L Bassett; Marcus W Bosenberg; Scott E Woodman; Willem W Overwijk; Gregory Lizée; Jason Roszik; Thomas F Gajewski; Jennifer A Wargo; Jeffrey E Gershenwald; Laszlo Radvanyi; Michael A Davies; Patrick Hwu
Journal:  Cancer Discov       Date:  2015-12-08       Impact factor: 39.397

8.  T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.

Authors:  Eric Tran; Paul F Robbins; Yong-Chen Lu; Todd D Prickett; Jared J Gartner; Li Jia; Anna Pasetto; Zhili Zheng; Satyajit Ray; Eric M Groh; Isaac R Kriley; Steven A Rosenberg
Journal:  N Engl J Med       Date:  2016-12-08       Impact factor: 91.245

9.  Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.

Authors:  Sheng-Bin Peng; James R Henry; Michael D Kaufman; Wei-Ping Lu; Bryan D Smith; Subha Vogeti; Thomas J Rutkoski; Scott Wise; Lawrence Chun; Youyan Zhang; Robert D Van Horn; Tinggui Yin; Xiaoyi Zhang; Vipin Yadav; Shih-Hsun Chen; Xueqian Gong; Xiwen Ma; Yue Webster; Sean Buchanan; Igor Mochalkin; Lysiane Huber; Lisa Kays; Gregory P Donoho; Jennie Walgren; Denis McCann; Phenil Patel; Ilaria Conti; Gregory D Plowman; James J Starling; Daniel L Flynn
Journal:  Cancer Cell       Date:  2015-09-03       Impact factor: 31.743

10.  Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors.

Authors:  Igor Puzanov; Jeffrey Sosman; Armando Santoro; Muhammad W Saif; Laura Goff; Grace K Dy; Paolo Zucali; Julie A Means-Powell; Wen Wee Ma; Matteo Simonelli; Robert Martell; Feng Chai; Maria Lamar; Ronald E Savage; Brian Schwartz; Alex A Adjei
Journal:  Invest New Drugs       Date:  2014-10-08       Impact factor: 3.850
View more
  4 in total

1.  HSP70 inhibition blocks adaptive resistance and synergizes with MEK inhibition for the treatment of NRAS-mutant melanoma.

Authors:  Joshua L D Parris; Thibaut Barnoud; Julia I-Ju Leu; Jessica C Leung; Weili Ma; Nicole A Kirven; Adi Naryana Reddy Poli; Andrew V Kossenkov; Qin Liu; Joseph M Salvino; Donna L George; Ashani T Weeraratna; Qing Chen; Maureen E Murphy
Journal:  Cancer Res Commun       Date:  2021-10

2.  BRAF Inhibitors in Melanoma Management: When Friends Become Foes.

Authors:  Gagan Chhabra; Nihal Ahmad
Journal:  J Invest Dermatol       Date:  2021-12-03       Impact factor: 7.590

3.  Classification and Grading of Melanocytic Lesions in a Mouse Model of NRAS-driven Melanomagenesis.

Authors:  Charles-Antoine Assenmacher; Sara F Santagostino; Mark A Oyama; Jean-Christophe Marine; Elise Bonvin; Enrico Radaelli
Journal:  J Histochem Cytochem       Date:  2020-12-07       Impact factor: 2.479

4.  Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition.

Authors:  Rebecca L Shattuck-Brandt; Sheau-Chiann Chen; Emily Murray; Christopher Andrew Johnson; Holly Crandall; Jamye F O'Neal; Rami Nayef Al-Rohil; Caroline A Nebhan; Vijaya Bharti; Kimberly B Dahlman; Gregory D Ayers; Chi Yan; Mark C Kelley; Rondi M Kauffmann; Mary Hooks; Ana Grau; Douglas B Johnson; Anna E Vilgelm; Ann Richmond
Journal:  Clin Cancer Res       Date:  2020-03-31       Impact factor: 13.801
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.